UBS Group
ETRA

UBS Group’s Electra Therapeutics, Inc. Common stock ETRA Stock Holding History

UBS Group’s Portfolio ETRA Stock Details ETRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$31.8K Buy
+2,831
New +$34.8K ﹤0.01% 8052

Other funds holding ETRA

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Monashee Investment Management
Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

UBS Group's ETRA Position: Q3 2026 in Review

UBS Group opened a new position in Electra Therapeutics, Inc. Common stock (ETRA) in Q3 2026: 2,831 shares worth $31.8K. The stake represents ﹤0.01% of the portfolio and ranks #8052 among its holdings.

7 funds tracked by Wall St. Rank hold ETRA as of Q3 2026.

  • UBS Group held 2,831 shares of Electra Therapeutics, Inc. Common stock worth $31.8K as of Q3 2026.
  • Electra Therapeutics, Inc. Common stock was a new UBS Group position in Q3 2026.
  • Electra Therapeutics, Inc. Common stock made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8052 holding.
  • 7 funds tracked by Wall St. Rank held Electra Therapeutics, Inc. Common stock as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.